07:00 , Oct 13, 2014 |  BC Week In Review  |  Company News

Emmes Corp., NIH cancer news

CRO Emmes said clinical investigators from the AIDS Malignancy Consortium (AMC) began a study to investigate strategies to prevent high-grade squamous intraepithelial lesions (HSIL) from progressing to anal cancer. Emmes is coordinating the trial under...
07:00 , Jul 24, 2000 |  BC Week In Review  |  Clinical News

IM862: Began Phase III trial

Cytran Inc., Kirkland, Wash.   Product: IM862   Business: Cancer   Therapeutic category: Angiogenesis   Target: Unknown   Description: Naturally occurring peptide consisting of two amino acids (glutamyl tryptophan) that inhibits angiogenesis and regulates cytokines...
07:00 , Jul 21, 2000 |  BC Extra  |  Clinical News

Cytran starts Phase III

Cytran (Kirkland, Wash) started enrollment of 200 patients in a multi-national Phase III trial of intranasal IM862 to treat AIDS-related Kaposi's sarcoma. The placebo-controlled, double-blind study of IM862, a naturally occurring peptide consisting of two...